The nonapeptide bradykinin (NH 2 -Arg-Pro-Pro-Gly-PheSer-Pro-Phe-Arg-COOH), a prototypic member of the kinin family, mediates important biological processes such as hypotension, edema formation, pain sensations, smooth muscle contraction, and cell growth (1). Kinins are locally released on the surface of target cells due to limited proteolysis of their parental molecules, kininogens, by the kallikreins (2). The broad spectrum of their (patho)physiological activities is mediated by cognate kinin receptors that classify pharmacologically as B1 and B2 subtypes (3). B1 receptors respond preferentially to des-Arg 10 -kallidin, whereas B2 receptors are stimulated by bradykinin and kallidin (lysylbradykinin). The multiplicity of biological effects elicited by the kinins is reflected by the complexity of their signaling pathways. B2 receptors couple to various G proteins such as G q , thereby triggering the inositol trisphosphate/Ca 2ϩ pathway via phospholipase C- and/or the arachidonic acid/prostaglandin pathway via phospholipase A 2 (4). Recent findings indicate that B2 receptors might also couple to the cAMP pathway via G s (5). In human foreskin fibroblasts, bradykinin induces, via phospholipase C, a transient rise in [Ca 2ϩ ] i that is counteracted by Ca 2ϩ extrusion (6). The increased [Ca 2ϩ ] i activates the nitric oxide/cGMP pathway and, together with diacylglycerol, drives the translocation and activation of protein kinase C, specifically of its isoforms ␣, ⑀, and (7).Given the remarkable pharmacological profile of these substances, it is evident that the activity of these peptides demands a careful control. Elaborate mechanisms exist that direct the kininogens to the surface of their target cells and allow kinin release at or next to its site of action (8). The liberated kinins are rapidly degraded in vivo by peptidases such as angiotensin-converting enzyme (kininase II), carboxypeptidase N (kininase I), and aminopeptidase P, which truncate and thereby inactivate the kinin peptides (9); the half-life of bradykinin in the plasma is Ͻ15 s (10). At the level of their receptors, the actions of kinins are restricted with respect to time and space by mechanisms involving receptor desensitization (11), internalization of the receptor-ligand complex (12, 13), loss of extracellular ligand-binding sites (14), and modulation of receptor affinity (11). Although tachyphylaxis and redistribution are well documented for the B2 receptor, the molecular mechanisms underlying these phenomena are not well understood. We hypothesized that reversible phosphorylation of kinin receptors might contribute to these phenomena.Here we have set out to investigate the agonist-induced phosphorylation of the bradykinin B2 receptor in a nontransformed human cell line (HF-15 fibroblasts) that endogenously expresses a high copy number of the B2 receptor. Using an anti-peptide antibody cross-reactive with the native receptor, we demonstrate the ligand-induced phosphorylation on Ser and Thr residues located in the carboxyl-terminal domain of th...